ALKS
Alkermes plcHealthcare · $6.9B market cap
Verdict
Share price
$41.75
close of Oct 3, 2026
Fair value
$26.63
Sticker Price
Payback Price
$10.65
buy price
ALKS is Overpriced: at $41.75 it trades 57% above its fair value of $26.63. Its buy price (Payback Price) is $10.65, 74% below today's price. Business quality is solid: 3 of 5 key numbers clear the 10% bar.
How we valued it
Free Cash Flow. Sales grew 10% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.
Business quality
3 of 5 clear the 10% bar. What are the Big Five?
Follow ALKS
Get notified when it reaches its buy price of $10.65. Free.
Create a free accountInsider activity
Since Jul 1, 2026: no open-market purchases, 10 sales worth $4.2M and 8 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Gaffin David Joseph
EVP, CLO, Alkermes, Inc. · 2026-09-03
Sold
$98K
Hopkinson Craig C.
EVP R&D, Chief Medical Officer · 2026-09-01
Sold
$423K
Nichols Christian Todd
SVP, Chief Commercial Officer · 2026-08-17
Sold
$33K
Nichols Christian Todd
SVP, Chief Commercial Officer · 2026-08-17
Sold
$340K
Gaffin David Joseph
EVP, CLO, Alkermes, Inc. · 2026-08-03
Sold
$99K
Show all 10 salesShow fewer
Hopkinson Craig C.
EVP R&D, Chief Medical Officer · 2026-08-03
Sold
$437K
snyderman nancy lynn MD
director · 2026-08-03
Sold
$2.2M
Gaffin David Joseph
EVP, CLO, Alkermes, Inc. · 2026-07-06
Sold
$110K
Hopkinson Craig C.
EVP R&D, Chief Medical Officer · 2026-07-01
Sold
$36K
Hopkinson Craig C.
EVP R&D, Chief Medical Officer · 2026-07-01
Sold
$427K
Other filings
Hopkinson Craig C.
EVP R&D, Chief Medical Officer · 2026-09-01
Option exercise
$123K
Jackson Blair Curtis
President & CEO, Alkermes plc · 2026-08-05
Award
$4.6M
Jackson Blair Curtis
President & CEO, Alkermes plc · 2026-08-05
Award
$6.2M
Hopkinson Craig C.
EVP R&D, Chief Medical Officer · 2026-08-03
Option exercise
$2K
Hopkinson Craig C.
EVP R&D, Chief Medical Officer · 2026-08-03
Option exercise
$120K
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of…
Drug Manufacturers - Specialty & Generic
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works